# FemTech biotech & women's health

Specialized biologic, diagnostic and live-biotherapeutic products for conditions that affect exclusively or disproportionately women — non-invasive endometriosis testing, ovarian-longevity therapeutics, vaginal-microbiome LBPs and cfDNA prenatal screening, under FDA, EU IVDR/EMA and NMPA oversight.

Source: https://en.bioecon.ru/technology/femtech-biotech-womens-health/
Updated: 2026-08-18



## Overview and value chain

Markers: [EC: EU Gender Equality Strategy & IVDR 2017/746 | OECD: Biotech & health — women's health biotechnology | Regulator: FDA (USA), EMA (EU), NMPA (China)]

FemTech biotech develops biologics, drugs and diagnostics for conditions that affect exclusively or disproportionately women, targeting a medical gender gap where endometriosis alone affects roughly 10% of reproductive-age women yet historically took 7–10 years to diagnose through invasive laparoscopy. The 2026 frontier concentrates on four directions: non-invasive endometriosis diagnostics from saliva miRNA (Ziwig Endotest, fast-track reimbursed for 25,000 patients across 80 French medical centres since February 2025, reading 109 miRNA markers with reported above-95% diagnostic accuracy in the ENDOmiRNA study); ovarian-longevity and fertility therapeutics that slow ovarian ageing to extend the natural fertility window and defer menopause; vaginal-microbiome live biotherapeutic products (LBPs) built on Lactobacillus crispatus consortia to restore an acidic vaginal pH below 4.5 and prevent bacterial vaginosis and preterm birth; and next-generation non-invasive prenatal testing (NIPT) that sequences cell-free fetal DNA (cfDNA) from maternal blood, where BGI's NIFTY has analysed more than 10 million pregnancies. The stack is regulated end-to-end — FDA drugs and devices in the US, the EU In Vitro Diagnostic Regulation (IVDR 2017/746) Class C for miRNA tests plus EMA for therapeutics in Europe, and NMPA registration in China.

The key directions of FemTech biotech & women's health are:
1. **Non-invasive endometriosis diagnostics:** saliva miRNA sequencing and menstrual-blood liquid biopsy (Ziwig Endotest, NextGen Jane Smart Tampon) that replace diagnostic laparoscopy with a mail-in lab test returning a staged diagnosis in days.
2. **Ovarian-longevity and fertility therapeutics:** target discovery and non-hormonal drug design (Celmatix Resolve platform, now partnered with Gedeon Richter) to slow ovarian ageing, protect the follicle pool during chemotherapy, and defer menopause.
3. **Vaginal-microbiome live biotherapeutics:** L. crispatus consortia formulated as lyophilized vaginal LBPs (Novonesis/Lactobio) to restore a healthy acidic microbiome and reduce bacterial-vaginosis and preterm-birth risk.
4. **Non-invasive prenatal testing (NIPT):** high-throughput cfDNA sequencing of fetal DNA in maternal blood (BGI NIFTY) to screen for fetal chromosomal aneuploidies early in pregnancy.

### Sectoral value chain

```
[Sample sourcing] ──> [Omics profiling] ──> [AI biomarker decoding]
      │                     │                       │
(saliva, menstrual,     (RNA-seq, cfDNA)    (miRNA → disease score)
 venous blood kits)                                   │
                                                       ▼
[Clinical delivery] <─── [GMP formulation] <─── [Therapeutic R&D]
(reimbursement, CE-IVD)     (LBP, peptide)     (ovarian, microbiome)
```

### Value chain levels

| Level | Description | Key inputs/outputs |
|:---|:---|:---|
| **Sample sourcing** | Painless at-home or clinic collection kits for saliva (RNA-stabilizing buffer), menstrual blood (smart tampons) or venous blood. | **In:** Patient biofluid, RNA-stabilizing tubes.<br>**Out:** Stabilized nucleic-acid sample. |
| **Omics profiling** | Total and small-RNA extraction, small-RNA library preparation and next-generation sequencing (NGS) of miRNA or cfDNA. | **In:** Stabilized sample, RNA-seq reagents.<br>**Out:** FASTQ files of small RNA / cfDNA reads. |
| **AI signature** | Machine-learning models (SVM, CNN, random forest) that turn the miRNA expression matrix into a disease probability and stage. | **In:** RNA-seq data, validated biomarker panel.<br>**Out:** Disease probability index and stage. |
| **Ovarian R&D** | Target discovery for slowing ovarian ageing, and design of non-hormonal peptides and hormonal modulators (e.g. AMH agonists). | **In:** Oocyte cultures, AI target models.<br>**Out:** Clinical candidates for ovarian longevity. |
| **LBP microecology** | Selection of L. crispatus strains and formulation of stable cryoprotected lyophilized vaginal suppositories or capsules. | **In:** Lactobacillus strains, GMP fermenters, cryoprotectants.<br>**Out:** Drug-form vaginal LBP. |
| **Clinical delivery** | CE-IVD / FDA licensing of the diagnostic, reimbursement negotiation with insurers, and Rx market access for therapeutics. | **In:** Clinical-trial data, IVD dossier.<br>**Out:** Reimbursed, clinically accessible FemTech tests and drugs. |

Cross-cutting technologies of the sector:
- **Saliva miRNA liquid biopsy:** high-sensitivity profiling of non-coding microRNAs carried in salivary exosomes; a 109-miRNA panel reports endometriosis with diagnostic accuracy above 95%, replacing invasive laparoscopy with a mail-in test.
- **L. crispatus live biotherapeutics:** vaginal LBPs built on L-microbe-producing L. crispatus strains that hold vaginal pH below 4.5, blocking colonization by pathogenic anaerobes and cutting the risk of ascending reproductive infections and preterm birth.
- **Anti-Müllerian hormone (AMH) engineering:** recombinant AMH molecules and receptor agonists that temporarily place the ovary in a dormant state during chemotherapy or to control ovarian reserve, preserving female fertility.

---

## US

The United States holds the deepest FemTech venture base and the largest dedicated women's-health pharma, commercializing ovarian-longevity therapeutics and molecular tampons while NIH grants de-risk early diagnostics.

### Ovarian-longevity R&D, molecular tampon, dedicated FemTech pharma, NIH funding
- **Celmatix and ovarian longevity:** Celmatix's Resolve platform uses multi-omic and clinical big data to map ovarian reserve and design non-hormonal candidates against ovarian ageing, and Hungarian pharma Gedeon Richter has acquired Celmatix's women's-health drug-discovery portfolio spanning fertility and endometriosis programs.
- **NextGen Jane (Smart Tampon):** NextGen Jane turns an ordinary tampon into a liquid-biopsy device, isolating endometrial cells and extracellular RNA from menstrual blood for non-invasive endometriosis and fibroid diagnosis; it validated a DNA/RNA/microbiome menstrual system in 2025 and received its second NIH SBIR Direct-to-Phase-II grant in May 2025.
- **Organon (NYSE: OGN):** spun out of MSD/Merck in 2021, Organon is the largest dedicated women's-health company, reporting $6.2 billion in full-year 2025 revenue and $1.91 billion adjusted EBITDA (30.7% margin), with the postpartum-haemorrhage Jada System and the Nexplanon contraceptive implant.

---

## CN

China develops FemTech under explicit state policy to support fertility and cut maternal and infant mortality, with BGI Genomics running the world's largest non-invasive prenatal testing programme and CAS institutes researching premature ovarian insufficiency.

### NIPT leadership (BGI Genomics), CAS reproductive institutes, vaginal probiotics
- **BGI Genomics (NIFTY):** BGI Genomics' NIFTY cfDNA test has analysed more than 10 million pregnancies worldwide, screening fetal trisomies (including Down syndrome) from maternal-blood cfDNA, and the upgraded NIFTY version has entered NMPA priority review.
- **CAS reproductive institutes:** the Shanghai institutes of the Chinese Academy of Sciences coordinate research into premature ovarian insufficiency (POI) and early menopause, and Chinese clinics run trials of collagen-scaffold mesenchymal-stem-cell therapy to regenerate the endometrium after injury.
- **Vaginal-probiotic production:** Chinese manufacturers produce large volumes of reproductive-health probiotics and are writing vaginal-microecology standards into national gynaecology guidelines.

---

## EU

The European Union is the global regulatory and technological pioneer of non-invasive endometriosis liquid biopsy, pairing the breakthrough Ziwig salivary test with strict IVDR Class C oversight and a live-biotherapeutic pipeline from Novonesis.

### Ziwig Endotest (France), Novonesis/Lactobio (Denmark), CE-IVDR Class C
- **Ziwig Endotest:** the French biotech Ziwig built the first salivary endometriosis test, sequencing 109 salivary miRNA markers and decoding them with AI; France granted fast-track reimbursement for 25,000 patients across 80 medical centres in February 2025, and the ENDOmiRNA study — the largest saliva-biomarker study worldwide — confirmed its accuracy in December 2025.
- **Novonesis (ex-Lactobio), Denmark:** Novonesis (which absorbed the Lactobio team via Chr. Hansen) runs a multi-strain L. crispatus vaginal synbiotic programme, with a randomized placebo-controlled trial (NCT05659745) and the VIBRANT Phase 1 trial of L. crispatus live biotherapeutics for bacterial vaginosis, using machine learning to predict probiotic function from vaginal strains.
- **IVDR Class C:** European regulators classify early miRNA diagnostics under the IVDR 2017/746 as Class C, requiring exhaustive multi-centre validation studies and independent notified-body audit before CE marking — the bar Ziwig cleared for its reimbursement.

---

## Leading companies and research institutes

| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|:---|:---|:---|:---|:---|
| **Ziwig** | 🇫🇷 France | *Endotest (salivary endometriosis test)* | Saliva 109-miRNA panel + AI decoder; FR reimbursement 25k patients / 80 centres | operating |
| **BGI Genomics** | 🇨🇳 China | *NIFTY cfDNA prenatal test* | High-throughput fetal cfDNA NGS; >10M pregnancies; NMPA priority review | commercial |
| **Organon** | 🇺🇸 USA | *Jada System, Nexplanon* | Dedicated women's-health pharma; $6.2B 2025 revenue; NYSE: OGN | commercial |
| **Celmatix** | 🇺🇸 USA | *Resolve ovarian platform* | AI ovarian-reserve mapping; non-hormonal candidates; portfolio → Gedeon Richter | operating |
| **Novonesis** | 🇩🇰 Denmark | *L. crispatus vaginal LBP* | Multi-strain synbiotic; VIBRANT Phase 1; ML strain selection | commercial |
| **NextGen Jane** | 🇺🇸 USA | *Smart Tampon platform* | Menstrual DNA/RNA/microbiome liquid biopsy; 2nd NIH SBIR grant May 2025 | operating |

---

## Tech stack and innovations

The FemTech biotech stack joins a small-RNA/cfDNA sequencing core, an AI biomarker-decoding layer, and a live-biotherapeutic formulation layer.

1. **Small-RNA (miRNA) extraction and NGS library preparation:**
   - Silica magnetic nanoparticles with tuned porosity capture the delicate 19–24-nucleotide miRNA fraction while washing away ribosomal and genomic RNA, and a Pippin-Prep-style preparative gel electrophoresis size-selects the 140–160 bp miRNA-plus-adapter library, stripping PCR adapter-dimer contamination.
2. **AI miRNA-signature decoding:**
   - A trained machine-learning model (SVM / random forest) takes the normalized expression of the 109-miRNA endometriosis panel and outputs a disease probability, stage and phenotype, turning a saliva sample into a clinical diagnosis without laparoscopy.
3. **Lyophilized L. crispatus live biotherapeutics:**
   - L. crispatus biomass is freeze-dried with protectant sugars (trehalose, sorbitol) on a temperature profile that prevents acid damage to cell walls, holding a stable titre above 1 billion CFU per suppository for ambient storage.

---

## Value chains and production pipelines

### Diagnostic miRNA pipeline of the Ziwig Endotest (ISO 13485 / GMP)

```
┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Saliva collection into │ ───> │ 2. Automated total +      │
│    RNA-stabilizer tube    │      │    small-RNA extraction    │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Precision size-        │ <─── │ 3. Small-RNA library prep │
│    selection (gel)        │      │    (adapter ligation, RT)  │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. NGS sequencing         │ ───> │ 6. AI 109-miRNA score &   │
│    (Illumina NextSeq)     │      │    clinical report        │
└───────────────────────────┘      └───────────────────────────┘
```

#### Stage 1: Saliva collection and transport
The patient spits into a Ziwig Endotest tube; on cap-rotation a stabilizing buffer of chaotropic salts and RNase inhibitors is released, instantly denaturing salivary proteins and preserving exosomal extracellular RNA, and the tube is mailed to the central accredited laboratory.

#### Stage 2: Automated total and small-RNA extraction
A robotic liquid handler (e.g. Hamilton Microlab) transfers stabilized saliva to an extraction plate; isopropanol and silica magnetic beads bind RNA in chaotropic salt, three alcohol washes remove salts, proteins and mucins, and RNA is eluted in RNase-free water with quality checked on an Agilent Bioanalyzer for a crisp small-RNA peak.

#### Stage 3: Small-RNA library preparation
A T4 RNA ligase attaches a 3' and then a 5' single-stranded RNA adapter to the small-RNA fraction; reverse transcription synthesizes cDNA, and 15 cycles of PCR with unique TruSeq index primers barcode each patient's library.

#### Stage 4: Precision size selection
The PCR product is loaded onto a preparative gel-electrophoresis system (e.g. Pippin Prep); a built-in laser detects DNA fragments migrating through agarose, and at 140–160 bp the instrument switches current to collect the clean miRNA-library fraction while discarding adapter dimers at about 120 bp.

#### Stage 5: NGS sequencing
Purified libraries are quantified by qPCR, up to 96 patient libraries are pooled equimolarly, denatured, and loaded on an Illumina NextSeq 550 flow cell for single-end 50 bp sequencing at a depth of at least 5 million reads per sample.

#### Stage 6: AI signature and clinical report
Reads are demultiplexed, adapter-trimmed, quality-filtered and aligned to the miRBase small-RNA database and the hg38 reference; a count matrix of the 109-miRNA panel is fed to a trained SVM model that outputs endometriosis probability, stage and phenotype; a clinical geneticist verifies the report and returns it to the gynaecologist, often sparing the patient a diagnostic laparoscopy.